Circulating high-mobility group box 1 and cardiovascular mortality in unstable angina and non-ST-segment elevation

Tousei Hashimoto1, Junnichi Ishii, Fumihiko Kitagawa

  • 1Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Japan.

Atherosclerosis
|February 29, 2012
PubMed

Insights

High-mobility group box 1 (HMGB1) may predict cardiovascular death in patients with unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI). Elevated HMGB1 levels on admission indicate a higher risk for mortality in these patients.

Area of Science:

  • Cardiology
  • Biomarkers
  • Acute Coronary Syndromes

Background:

  • High-mobility group box 1 (HMGB1) is a damage-associated molecular pattern molecule implicated in acute coronary syndrome (ACS) pathophysiology.
  • Previous studies linked circulating HMGB1 to cardiac mortality in ST-segment elevation myocardial infarction.
  • The prognostic significance of HMGB1 in unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI) remained unclear.

Purpose of the Study:

  • To investigate the prognostic value of circulating HMGB1 concentrations in patients hospitalized for UA/NSTEMI.
  • To determine if HMGB1 is an independent predictor of cardiovascular mortality in this patient cohort.

Main Methods:

  • HMGB1, hsCRP, troponin I, and BNP levels were measured on admission in 258 UA/NSTEMI patients.
  • Patients were followed for a median of 49 months to assess cardiovascular mortality.
  • Cox regression analysis was used to identify independent predictors of mortality, adjusting for clinical factors.

Main Results:

  • Cardiovascular death occurred in 14.7% of patients during follow-up.
  • HMGB1, cardiac troponin I, Killip class >1, and age were independent predictors of cardiovascular mortality.
  • Patients with elevated HMGB1 (≥ 2.4 ng/mL) exhibited significantly higher in-hospital and cardiovascular mortality rates compared to those with lower levels.

Conclusions:

  • Circulating HMGB1 concentration upon admission is a potential and independent predictor of cardiovascular mortality in UA/NSTEMI patients.
  • HMGB1 may serve as a valuable biomarker for risk stratification in patients hospitalized for UA/NSTEMI within 24 hours of symptom onset.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...